Immunomaks powder and / v / m 3 units 200ed liofil. fl

Description

Composition
Active substance:
100 IU or 200 IU Immunomax.
Description:
formulation is a lyophilized white powder.
Product form:
The drug is released in the form of a sterile lyophilized powder of white color 200 U Immunomax vial or ampoule.
Contraindications
The drug should not be used in individuals with hypersensitivity to Immunomax. Children up to 12 years.
Indications
correction weakened immunity;
for the treatment of pathological states (. acuminata, warts, dysplasia, etc.) caused by human papilloma virus;
for the treatment of infections caused by the herpes simplex virus, chlamydia, mycoplasma, ureaplasma, and other bacteria and viruses.
pharmachologic effect
Pharmacological group:
immunomodulator.
Pharmacological properties:
Immunomaks enhances the immune defense against viral and bacterial infections. Immunofar-makologicheskie mechanisms of drug action consists in the fact that Immunomax activates the following components of the immune system: NK-cells, which are 2-3 hours after exposure Immunomax strongly express activation molecules CD69. Cytolytic activity increased in 3 times NK-cells;
circulating monocytes 2-4 hours after activation Immunomax begin to secrete cytokines: interleukin-8, interleukin-1beta and tumor necrosis factor alpha;
neutrophilic granulocytes are activated through the medium of monocytes direct effect on neutrophilic granulocytes preparation has not. The secreted IL-8 by monocytes induces activation of neutrophilic granulocytes, which clearly evident 24 hours after exposure Immunomax;
tissue macrophages, which manifests itself in changing the morphology of these cells, enhancing production of bactericidal substances, 5′-nucleotidase activity change;
antibodies against foreign antigens, soluble and corpuscular;
Immunomaks enhances protection against infections caused by viruses (human papilloma virus, herpes simplex virus, parvovirus, canine distemper virus, etc.) Or bacteria (Escherichia coli, Salmonella, Staphylococcus aureus, chlamydia, mycoplasma, ureaplasma et al.). This action of the drug is in adults and infants when administered Immunomax various ways: intramuscularly, intravenously, intraperitoneally, per os.
Pharmacokinetics:
The pharmacokinetics of the drug has not been studied in relation to its peptidoglycan nature and very small doses applicable.
Pregnancy and breast-feeding
No data are available on the effects of Immunomax pregnant women. As in the case of other drugs, Immunomax should not be used during pregnancy unless the benefits accruing to the patient, do not exceed the potential risk to the fetus. Immunomaks not recommended for breastfeeding mothers.
Conditions of supply of pharmacies
Available on medical prescription.
Storage conditions
Store at +4 to +8 degrees. FROM.
Dosing and Administration
The recommended dose for adults and children 12 years and older is 100-200 U intramuscularly once a day. Before use, the contents of the vial (vial) was dissolved in 1 ml of water for injection was administered intramuscularly at 100-200 IU depending on the severity of the disease. The course of treatment – 6 injections of 1, 2, 3, 8, 9 and 10 days of treatment. for the treatment of recurrent anogenital warts course of 6 injections of 200 IU Immunomax coupled with destruction of warts one of the conventional methods: cryosurgery, elektrokoagu-lyatsiya, or laser destruction solkoderm; for the treatment of infections caused by bacteria or viruses, a course of 6 injections of 100-200 U Immunomax; correction weakened immunity a course of 3-6 injections of 100-200 U Immunomax.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist